Respiratory syncytial virus infections in hematopoietic stem cell transplant recipients and other severely immunocompromised patients

Pediatric Pathology and Molecular Medicine

Volumn 19, Issue 2-3, 2000, Pages 115-132

  DeVincenzo, J P ^a  

^a LE BONHEUR CHILDREN S HOSPITAL   (United States)

Author keywords

Bone marrow transplantation; Pneumonia; Respiratory virus; RSV

Indexed keywords

IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RIBAVIRIN;

ARTICLE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; EPIDEMIC; EUROPE; FATALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; NURSING HOME; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; THROAT CULTURE; UNITED STATES; VIRUS INFECTION; VIRUS PNEUMONIA;

EID: 0033798119     PISSN: 15227952     EISSN: None     Source Type: Journal    
DOI: 10.1080/15513810009168628     Document Type: Article

References (64)

1. Risk of primary infection and reinfection with respiratory syncytial virus
2. Respiratory syncytial virus - Missouri
3. An outbreak of respiratory syncytial virus in a bone marrow transplant center
4. Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients
5. Inability to detect respiratory syncytial virus in peripheral blood mononuclear cells of infants with bronchiolitis
6. Prevention and treatment of respiratory syncytial virus infections
7. Pathological changes in virus infections of the lower respiratory tract in children
8. Reduction of Respiratory Syncytial Virus (RSV) in tracheal aspirates in intubated infants using humanized monoclonal antibody to RSV F Protein
9. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants
10. Respiratory Syncytial Virus (RSV) pneumonia following bone marrow transplantation: Reduction in nasal RSV quantity and clinical improvement after treatment with RSV immune globulin. Presented at Southern Society for Pediatric Research, New Orleans, LA Feb 2000
11. Respiratory viral infections in immunocompetent and immunocompromised persons
12. Respiratory virus infections after marrow transplant: The Fred Hutchinson Cancer Research Center experience
13. Respiratory virus infections in bone marrow transplant recipients: The European perspective
14. Respiratory syncytial virus (RSV) pneumonia among hospitalized adult patients with leukemia
15. Community respiratory virus infections in immunocompromised patients with cancer
16. Patients with multiple myeloma can safely undergo autologous transplantation despite ongoing RSV infection
17. Rapid diagnosis of respiratory syncytial virus (RSV) infection in immunocompromised adults
18. In vivo inhibitioin of respiratory syncytail virus by ribavirin
19. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice
20. Respiratory syncytial virus infections in infants: Quantitation and duration of shedding
21. Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection. A randomized double-blind study
22. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease
23. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infections in infants
24. Ribavirin aerosol for acute bronchiolitis
25. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease
26. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective, double-blind, randomized trial
27. Ribavirin therapy for acute bronchiolitis: Need for appripriate controls
28. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone
29. Mechanism of cough and bronchoconstriction induced by distilled water aerosol
30. Delivery of aerosolized drugs to neonatal and pediatric patients
31. Comparison of nebulizer delivery methods through a neonatal endotracheal tube: A bench study
32. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection
33. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children
34. Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin
35. Pediatric critical care physicians' attitudes about guidelines for the use of ribavirin in critically ill children with respiratory syncytial virus pneumonia
36. Ribavirin. Red Book Committee recommendations questioned
37. Aerosolized ribavirin in mechanically ventilated children
38. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview
39. Ribavirin treatment of viral pneumonitis in severe combined immunodeficiency disease
40. Treatment of respitatory viral infection in an immunodeficient infant with ribavirin aerosol
41. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation
42. Risk of respiratory syncytial virus infection for infants from low income families in relationship to age, sex, ethnic group and maternal antibody level
43. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat
44. Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection in cotton rats
45. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections
46. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model
47. Immunoglobulin administration and ribavirin therapy: Efficacy in respiratory syncytial virus infection of the cotton rat
48. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children
49. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group
50. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay
51. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin
52. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation
53. Respiratory Syncytial Virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantatlon - A compassionate use experience
54. Respiratory syncytial virus infections in adult bone marrow transplant recipients
55. Respiratory syncytial virus infection in bone marrow transplantation: A case report
56. Respiratory syncytial virus infections on an adult medical ward
57. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: A report of three cases and review
58. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: A clinical approach and review of the literature
59. Respiratory syncytial virus infection in immunocompromised adults
60. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients
61. Palivizumab, a humanized respiratory syncytial virus monoclonal antobody, reduces hospitalization from respiratory syncytial virus infection in high risk infants
62. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus